ScholarIQanswers from OpenAlex & ORCID
Rui‐Hua Xu
ResearcherPublications, citations & collaboration network
Rui‐Hua Xu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Rui‐Hua Xu have?
ScholarIQindexed works
Rui‐Hua Xu has 1,458 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Rui‐Hua Xu have?
ScholarIQcitation count
Rui‐Hua Xu has 55,649 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Rui‐Hua Xu?
ScholarIQh-index
Rui‐Hua Xu has an h-index of 104 in OpenAlex.
What is the i10-index of Rui‐Hua Xu?
ScholarIQi10-index
Rui‐Hua Xu has an i10-index of 569 in OpenAlex.
What is the ORCID of Rui‐Hua Xu?
ScholarIQorcid
The ORCID for Rui‐Hua Xu is on the source record.
What is the OpenAlex record for Rui‐Hua Xu?
ScholarIQopenalex
The OpenAlex for Rui‐Hua Xu is on the source record.
What are the most-cited papers on Rui‐Hua Xu?
ScholarIQmost cited works
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Rui‐Hua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun, Liwei Wang, Leizhen Zheng, Hong Guo, Jingbo Wu, Nong Xu, Jianwei Yang, Honggang Zhang, Ying Cheng, Ningju Wang, Lei Chen, Zhining Fan, Piaoyang Sun, Hao Yu
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Yihebali Chi, Liwei Wang, Kun‐Huei Yeh, Feng Bi, Ying Cheng, Anh T. Le, Jen-Kou Lin, Tianshu Liu, Dong Ma, Christian Kappeler, J. Kalmus, Tae Won Kim
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Hui Luo, Jin Lü, Yuxian Bai, Teng Mao, Jun Wang, Qingxia Fan, Yiping Zhang, Kuaile Zhao, Zhendong Chen, Shegan Gao, Jiancheng Li, Zhichao Fu, Kangsheng Gu, Zhihua Liu, Lin Wu, Xiaodong Zhang, Ji‐Feng Feng, Zuoxing Niu, Yi Ba, Helong Zhang, Ying Liu, Li Zhang, Xuhong Min, Jing Huang, Ying Cheng, Dong Wang, Yu Shen, Qing Yang, Jianjun Zou, Rui‐Hua Xu, ESCORT-1st Investigators, Xianglin Yuan, Dong Ma, Emily Liu, Feng Ye, Tianshu Liu, Xiuwen Wang, Likun Liu, Bing Xia, Fengming Ran, Sanyuan Sun, Zhanhui Miao, Jun Bie, Yong Gao, Junyan Yu, Li Chen, Yifu He, Wei Ren, Suxia Luo, Guangqiang Zhao, Youen Lin, Long Chen, Zhiyuan Guo, Chunhong Hu, Ying Wang, Nong Xu, Baofu Chen, Xianbao Zhan, Yuping Chen, Hongda Lu, Shukui Qin, Guolei Wang, Liming Chen, Li Bai, Jingdong Zhang
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Guoping Sun, Toshihiko Doi, Jianming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jinwan Wang, Hiroto Miwa, Shukui Qin, Ik‐Joo Chung, Kun‐Huei Yeh, Jifeng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohtsu, Yung‐Jue Bang
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, George Pentheroudakis, Kentaro Yamazaki, Rui‐Hua Xu, Tae‐Woo Kim, Muhammad Ismail, Iain Tan, Kun‐Huei Yeh, Axel Grothey, S. Zhang, Joong Bae Ahn, M.Y. Mastura, Dawn Q. Chong, Liqun Chen, Scott Kopetz, Takako Eguchi-Nakajima, Hiromichi Ebi, Atsushi Ohtsu, Andrés Cervantes, Kei Muro, Josep Tabernero, Hironobu Minami, Fortunato Ciardiello, Jean‐Yves Douillard